EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells

Kohei Mitsuno, Masaya Suematsu, Yuki Naito, Azusa Mayumi, Hideki Yoshida, Shinya Osone, Toshihiko Imamura, Yozo Nakazawa, Shigeki Yagyu, Tomoko Iehara

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03927-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Kohei Mitsuno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Janus Kinase 2, Antigens, CD19, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of molecular targeted therapeutics with chimeric antigen receptor T (CAR-T) cell therapy represents a novel strategy to amplify the anti-tumor efficacy of immunotherapy. While CD19-targeted CAR-T cells and Janus kinase (JAK) inhibitors have independently shown efficacy against certain B-cell leukemias, such as Philadelphia chromosome-like acute lymphoblastic leukemia, the concurrent use of JAK1/2 inhibitors, such as ruxolitinib, has been implicated in reducing CAR-T cell potency by inhibiting the JAK1-dependent T cell activation pathway. This study explores the combinatorial use of a selective type II JAK2 inhibitor, CHZ868, with CD19 CAR-T cells, revealing a synergistic enhancement of anti-leukemic activity across B-cell tumor models irrespective of JAK2 mutational status. CHZ868-mediated JAK2 inhibition did not induce the exhaustion of CAR-T cells, maintaining efficacy over repeated tumor challenges and significantly extending survival in mouse models engrafted with JAK2 inhibitor-resistant leukemia cells (median survival, CD19 CAR-T + CHZ868 vs. CD19 CAR-T + DMSO: 32 days vs. 26 days, p = 0.0303). Transcriptomic analyses suggest that CHZ868 impedes CAR-T cell differentiation while preserving their proliferative capacity, a crucial factor in maintaining CAR-T cell functionality. Therefore, the selective inhibition of the JAK2 pathway may potentiate CAR-T cell therapy and offer a viable treatment strategy for patients with resistant B-cell leukemias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Antigens, CD19Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsMiceHumansXenograft Model Antitumor AssaysCell Line, TumorSignal TransductionPyrazolesFemaleBridged-Ring CompoundsPyrimidines

Stichwörter der Autor:innen

CAR-T cell therapyJAK2 inhibitorMemory T cell fractionPh-like ALL

Substanzen

Janus Kinase 2Antigens, CD19Receptors, Chimeric AntigenJAK2 protein, human11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…PyrazolesBridged-Ring CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. masa16@koto.kpu-m.ac.jp.
  • Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
  • Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan.
  • Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. shigeky@koto.kpu-m.ac.jp.
  • Innovative Research and Liaison Organization, Shinshu University, Matsumoto, Japan. shigeky@koto.kpu-m.ac.jp.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Mitsuno, K., Suematsu, M., Naito, Y., Mayumi, A., Yoshida, H., Osone, S., Imamura, T., Nakazawa, Y., Yagyu, S., & Iehara, T. (2025). Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03927-8

Vancouver

Mitsuno K, Suematsu M, Naito Y, Mayumi A, Yoshida H, Osone S, et al. Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03927-8

BibTeX
@article{Mitsuno2025,
  author = {Mitsuno, Kohei and Suematsu, Masaya and Naito, Yuki and Mayumi, Azusa and Yoshida, Hideki and Osone, Shinya and Imamura, Toshihiko and Nakazawa, Yozo and Yagyu, Shigeki and Iehara, Tomoko},
  title = {Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03927-8}
}
Kostenlos starten →